Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap ($669.13 Million)
Market Cap & Net Worth: Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. market cap. Hubei Biocause Heilen Pharmaceutical Co. Ltd. (SHE:301211) has a market capitalization of $669.13 Million (CN¥4.57 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #10489 globally and #2784 in its home market, demonstrating a 7.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s stock price CN¥10.95 by its total outstanding shares 417600000 (417.60 Million). Also see cash flow conversion of Hubei Biocause Heilen Pharmaceutical Co. for how efficiently the company converts equity into cash flow.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap History (2021–2026)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. market cap history from 2021 to 2026. Data shows change from $1.81 Billion to $669.13 Million (-18.34% CAGR). Check Hubei Biocause Heilen Pharmaceutical Co. stock price for real-time trading data and today's change.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hubei Biocause Heilen Pharmaceutical Co. equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.65x
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap is 1.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.39x
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap is 21.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.81 Billion | $540.62 Million | $121.65 Million | 3.35x | 14.88x |
| 2022 | $1.69 Billion | $514.91 Million | $125.79 Million | 3.28x | 13.43x |
| 2023 | $1.29 Billion | $663.03 Million | $176.12 Million | 1.95x | 7.33x |
| 2024 | $1.30 Billion | $445.86 Million | $91.55 Million | 2.91x | 14.19x |
| 2025 | $746.74 Million | $453.31 Million | $34.91 Million | 1.65x | 21.39x |
Competitor Companies of 301211 by Market Capitalization
Companies near Hubei Biocause Heilen Pharmaceutical Co. Ltd. in the global market cap rankings as of November 5, 2026. Also see Hubei Biocause Heilen Pharmaceutical Co. total assets for a full breakdown of the balance sheet.
Key companies related to Hubei Biocause Heilen Pharmaceutical Co. Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2021–2026)
Market capitalization of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2021 to today. Between 2021 and today, Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap moved from $1.81 Billion to $ 669.13 Million, with a yearly change of -18.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥669.13 Million | -10.39% |
| 2025 | CN¥746.74 Million | -42.52% |
| 2024 | CN¥1.30 Billion | +0.57% |
| 2023 | CN¥1.29 Billion | -23.55% |
| 2022 | CN¥1.69 Billion | -6.62% |
| 2021 | CN¥1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hubei Biocause Heilen Pharmaceutical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $669.13 Million USD |
| MoneyControl | $669.13 Million USD |
| MarketWatch | $669.13 Million USD |
| marketcap.company | $669.13 Million USD |
| Reuters | $669.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more